MEP Instruments will change its name to Metrohm Australia and Metrohm New Zealand, effective 1 January 2018. [ + ]

The TGA has announced changes to its Special Access Scheme that will make it easier for medical practitioners to prescribe cannabis-based medicines for patients in need, under certain conditions. [ + ]

The ANSTO Awards in Nuclear Science and Technology 2017 have been announced, celebrating a number of researchers for their work advancing nuclear science in Australia. [ + ]

Spanish researchers have developed a new tool that enables clinico-genomic data to be easily shared among different institutions. [ + ]

Analytical instrumentation provider AXT will soon be installing a Synergy-S single crystal X-ray diffraction system, manufactured by Rigaku Oxford Diffraction (ROD), at The University of Queensland (UQ). [ + ]

Researchers have identified a reversible 'master switch' on most developmental genes in the common fruit fly, a powerful model organism for studying how human genes are organised and function. [ + ]

UK scientists have discovered a set of epigenetic marks and proteins that behave like genetic switches, controlling which genes contribute to making antibodies. [ + ]

Fast-tracking biomarker research has the potential to transform cancer diagnosis and treatment, according to a report by the University of South Australia's Sansom Institute. [ + ]

University of Leicester experts in association with the spin-off company MIP Diagnostics have developed polymeric materials with molecular recognition capabilities which hold the potential to outperform natural antibodies in various diagnostic applications. [ + ]

Stem cell researchers Mark Dawn and Jessica Mar have both received $50,000 Metcalf Prizes from the National Stem Cell Foundation of Australia. [ + ]

Particle & Surface Sciences (PsS) has been appointed distributor for Izon Science products across Australia. [ + ]

Australian and Sri Lankan medical researchers have forged a new action plan to investigate the causes of a particular form of chronic kidney disease. [ + ]

Biotron has announced that several of its compounds have demonstrated significant antiviral activity against hepatitis B (HBV) in recently completed preclinical studies. [ + ]

Prima BioMed has presented new data from a phase I clinical trial investigating eftilagimod alpha, its anticancer candidate, in combination with pembrolizumab in unresectable or metastatic melanoma patients. [ + ]

myDNA has conducted a national study into the mental health of Australians, revealing that two-thirds of people believe that improvements could be made to their medication. [ + ]